VEGF-A induces its negative regulator, soluble form of VEGFR-1, by modulating its alternative splicing  by Saito, Tetsuya et al.
FEBS Letters 587 (2013) 2179–2185journal homepage: www.FEBSLetters .orgVEGF-A induces its negative regulator, soluble form of VEGFR-1, by
modulating its alternative splicing0014-5793/$36.00  2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
http://dx.doi.org/10.1016/j.febslet.2013.05.038
⇑ .Corresponding authors Address: Department of Cardiovascular Medicine,
Graduate School of Medicine, University of Tokyo, Japan.
E-mail address: ntakeda-tky@umin.ac.jp (N. Takeda).Tetsuya Saito a, Norihiko Takeda a,b,⇑, Eisuke Amiya a, Tomoko Nakao a, Hajime Abe a, Hiroaki Semba a,
Katsura Soma a, Katsuhiro Koyama a, Yumiko Hosoya a, Yasushi Imai a, Takayuki Isagawa a,
Masafumi Watanabe a, Ichiro Manabe a, Issei Komuro a,c, Ryozo Nagai a,d, Koji Maemura a,e,⇑
aDepartment of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Japan
b PRESTO, JST, Japan
cDepartment of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan
d Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi 329-0498, Japan
eDepartment of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japana r t i c l e i n f o
Article history:
Received 25 March 2013
Revised 28 April 2013
Accepted 9 May 2013
Available online 24 May 2013
Edited by Veli-Pekka Lehto
Keywords:
Angiogenesis
VEGF-A
VEGFR-1
sVEGFR-1
Alternative splicinga b s t r a c t
Vascular endothelial growth factor-A (VEGF-A) is one of the major angiogenic factors, and its actions
are primarily mediated through its two membrane receptors, VEGFR-1 and VEGFR-2. A soluble form
of VEGFR-1 (sVEGFR-1) sequesters the free form of VEGF-A, and acts as a potent anti-angiogenic fac-
tor. While sVEGFR-1 is synthesized as a splice variant of VEGF-R1 gene, the interactions between
VEGF-A and sVEGFR-1 remain largely unknown. Here, we show that VEGF-A upregulates sVEGF-R1
expression in human vascular endothelial cells but leaves full-length VEGF-R1 expression
unchanged, and that this induction was dependent on the VEGFR-2-protein kinase C-MEK signaling
pathway. The VEGF-A-induced sVEGFR-1 upregulation can operate as a negative feedback system,
which if modulated can become a novel therapeutic target for regulating pathological angiogenesis.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Vascular endothelial growth factor-A (VEGF-A) is a potent vas-
cular endothelial cell (EC)-speciﬁc mitogen that stimulates EC pro-
liferation, migration and angiogenesis, and it has also been shown
to improve EC function and survival in vitro as well as vascular
reactivity in vivo [1–3]. The actions of VEGF-A are primarily med-
iated through its two major tyrosine kinase receptors, namely
VEGF receptor-1 (VEGFR-1, also known as fms-like tyrosine kinase;
Flt1) and VEGF receptor-2 (VEGFR-2, also known as kinase insert
domain receptor; KDR) [4]. Of these two receptors, VEGFR-2 pos-
sesses stronger tyrosine kinase activity and thus mediates most
of the mitogenic signals of VEGF-A [1,5]. However, recent gene-tar-
geting studies indicated VEGFR-1-mediated signalings have also
signiﬁcant roles in pathological angiogenesis [6]. Indeed, we
previously reported that HIF-2a, a member of hypoxia-inducibletranscription factors dominantly expresses in vascular endothelial
cells, transactivates VEGFR-1 and enhances mature angiogenesis
[7].
The soluble form of VEGFR-1 (sVEGFR-1) is transcribed as a
splice variant of full-length VEGFR-1 by a premature polyadenyla-
tion of the VEGFR-1 transcript at the intron 13 [8]. Although solu-
ble VEGFR-1 strongly binds to VEGF-A and placental growth factor
(PlGF), it actually functions as a potent angiogenic inhibitor and
causes endothelial dysfunction since it lacks the seventh immuno-
globulin-like domain as well as the transmembrane and tyrosine
kinase regions [9–12].
In cases of pathological angiogenesis such as preeclampsia and
malignancies, sVEGFR-1 can potentially be used as a therapeutic
target or as a prognostic biomarker. For example, hypoxic condi-
tions of the placenta in preeclampsia not only increase VEGF-A
expression, but also induces increased sVEGFR-1 secretion. The
resultant net effect is a reduced bioavailability of free VEGF-A
and PlGF, thereby leading to hypertension, glomerular dysfunction
and proteinuria [13–16]. Indeed, increased levels of sVEGFR-1 and
reduced levels of PlGF have been demonstrated to be predictors of
the subsequent development of preeclampsia [17]. Moreover, a
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cantly with a more favorable prognosis and better responsiveness
to anti-cancer therapy in gliomas, breast cancer and pancreatic
cancer patients [18–21]. These results indicate that angiogenesis
is strictly regulated by the balance between pro- and anti-angio-
genic factors, and that any imbalances between them have the po-
tential to elicit pathological angiogenic disorders.
The phenomenon of feedback interactions between a ligand and
its endogenous inhibitor, such as seen with Wnt glycoproteins and
its antagonists during processes of cell proliferation and differenti-
ation, has been extensively reported elsewhere. Wnt signaling is
negatively regulated by soluble antagonists such as secreted
Frizzled-related protein-1 (sFRP-1) or DICKKOPF-1 [22], the
expressions of which are in fact induced by canonical Wnt signal-
ing and thereby creates a negative feedback loop to antagonize
persistent Wnt signal activation under physiological conditions
[23,24].
In a similar way, we therefore hypothesized that sVEGFR-1 may
act as a negative regulator in VEGF-A signaling. In this study, we
identiﬁed that VEGF-A, but not PlGF, affects the splicing processes
of the VEGFR-1 gene via the VEGFR-2-protein kinase C (PKC)-MEK
pathway, leading to the induction of sVEGFR-1 expression. The
induction of sVEGFR-1 splicing is dependent on the premature pol-
yadenylation of its intron 13 [8]. We also conﬁrmed that a VEGF-A
responsive element exists within intron 13 of the VEGFR-1 gene.
Our ﬁndings give insights into a novel negative feedback system
in physiological or pathological angiogenesis that, if modulated,
may be a novel therapeutic target in the treatment of numerous
pathological angiogenic disorders.
2. Materials and methods
2.1. Materials
Human recombinant VEGF-A, human recombinant PlGF, and
12-O-tetradecanoyl-phorbol-13-acetate (TPA) were obtained from
R&D Systems (Minneapolis, MN). CalphostinC, u0126, LY294002
and SB203580 were obtained from Calbiochem (La Jolla, CA).
2.2. Cell culture
Human aortic endothelial cells (HAECs), human umbilical vein
endothelial cells (HUVECs), and human aortic smooth muscle cells
(hASMCs) were obtained from BioWhittaker (Walkersville, MD).
Human aortic endothelial cells and HUVECs were maintained in
endothelial growth medium 2 (EGM-2, Cambrex) while HASMCs
were maintained in smooth muscle growth medium 2 (SMGM-2,
Cambrex). AD293 cells (human embryonic kidney cells), bEnd.3
cells (murine brain endothelial cells), EOMA cells (murine heman-
gioendothelioma endothelial cells) and RAW cells (murine macro-
phage cells) were purchased from ATCC and cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) (Sigma–Aldrich JAPAN, Tokyo,
Japan) containing 10% FBS, 50 U/ml penicillin, and 50 lg/ml strep-
tomycin. All cells were cultured at 37 C, 5% CO2 and cells from pas-
sages 5 to 10 were used for the experiments.
2.3. Northern blot analysis
Total cellular RNA was extracted by the RNeasy Mini Kit (QIA-
GEN, Tokyo, Japan) according to the manufacturer’s instructions.
Northern blot analysis using probe 1 was performed as described
previously [7]. The 350 bp (AL138712 bp157156–157505) frag-
ment of the proximal end of intron 13, the 465 bp (AL138712
bp153527–153991) fragment of the distal end of intron 13, and
the 436 bp (AL138712 bp152304–152739) fragment of exon 14 of
the human VEGFR-1 gene were ampliﬁed by PCR with, respectively,VEGFR-1 probes 2, 3, and 4 (see Fig. 1A). To correct for differences in
RNA loading, the membranes were rehybridized with radiolabeled
18S oligonucleotide.
2.4. Western blot analysis
Total cellular protein of HAECs was extracted using extraction
buffer (25 mM Tris, pH 7.4, 50 mM NaCl, 0.5% Na deoxycholate,
2% NP-40, and 0.2% SDS). Equal amounts of protein (10 lg) were
subjected to SDS–PAGE as described previously [7]. Full-length
VEGFR-1 and sVEGFR-1 were detected using monoclonal anti-
hVEGFR-1 mouse IgG antibody (Sigma–Aldrich, 1:1000) and anti-
mouse horseradish peroxidase-conjugated IgG (Cell Signaling,
1:5000) as a second antibody, followed by enhanced chemilumi-
nescence plus detection (GE healthcare Japan, Tokyo, Japan).
2.5. siRNA duplex and transfection
The siRNA directed against full-length VEGFR-1 was designed to
target a sequence in Exon27of theVEGFR-1gene, and the sequences
of the siRNA duplex were 50-UUGGGAUGUAGUCUUUACCdTdT-30
(sense strand) and 50-GGUAAAGACUACAUCCCAAdTdT-30 (anti-
sense strand). The scrambled control duplex did not target any gene,
and the sequences were 50-CUUACUAACAUGGUGUGUUdTdT-30
(sense strand) and50-AACACACCAUGUUAGUAAGdTdT-30 (antisense
strand). The siRNAduplexeswere synthesizedusing theSilencer siR-
NA Construction Kit (Ambion) according to the manufacturer’s
instructions. The siRNA directed against VEGFR-2 was purchased
from Dharmacon (Target sequences: GGGCAUGUACUGACGAUUA,
CUACAUUGUUCUUCCGAUA,GGAAAUCUCUUGCAAGCUAandGCGA
UGGCCUCUUCUGUAA).
HAECs were plated onto 6-cm cell culture dishes and grown to
70% conﬂuence before transfection by adding a total of 10 ll of
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) and
200 pmol siRNA duplex.
2.6. Construction of reporter plasmids
The pGL3-Basic plasmid was purchased from Promega (Madi-
son, WI). To generate the VEGFR-1 reporter plasmid (Fig. 4-A-
(1)), the promoter region of the VEGFR-1 gene from position
1160 to +305 was ampliﬁed by PCR and subcloned into the
pGL3-Basic plasmid between SacI and HindIII restriction sites. To
generate the reporter plasmid with a modulated poly(A) signal,
the intron 13 fragment (AL138712 bp152676–157553) of the
VEGFR-1 gene was ampliﬁed by PCR and inserted into the
VEGFR-1 reporter plasmid between SalI and XbaI restriction sites
in place of the SV40 late poly(A) signal (Fig. 4-A-(2)).
2.7. Transient transfection assay
HAECs were cultured in 12-well culture plates and transfected
with 2.0 lg of the reporter construct using the Neon Transfection
system (Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. To correct for variations in transfection efﬁciency,
we cotransfected 0.1 lg of pCMV-bgal in all experiments. Cell
extracts were prepared by a detergent lysis method (Promega
KK, Tokyo, Japan). The ratio of luciferase activity to b-galactosidase
activity in each sample served as a measure of normalized lucifer-
ase activity. Each construct was transfected at least 3 times, and
each transfection was done in triplicate.
2.8. Statistical analysis
Results are expressed as mean ± S.E. Two-tailed Student’s t test
for unpaired samples or one-way ANOVA was used for parameter
comparisons, and a P < 0.05 was considered signiﬁcant.
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Fig. 1. Identiﬁcation of full-length VEGFR-1 and several splice variants of sVEGFR-1 mRNA in Northern blot analysis and expression proﬁle in different cell types and organs.
(A) Top, Binding locations of probes 1–4 for Northern blot analysis. Probe 1 was located at the N-terminus site of the human VEGFR-1 cDNA. Probe 2 and 3 was located near
the 50- and 30-ends of intron 13, respectively. Probe 4 was located in exon 14. Arrows represent sites of the canonical cleavage-polyadenylation signal AAUAAA or the signal
variant AUUAAA within intron 13. Bottom, Representative results of Northern blot analysis using the 4 probes. Probe 1 hybridized with 3 major transcripts (arrows), but some
transcripts were not present when other probes were used (dotted arrows). Black arrowhead marks another sVEGFR-1 splice variant (approx. 3.0 kb) which lacks intron 13.
(B) Identiﬁcation of 3 major bands shown in Northern blot analysis: (F) VEGFR-1 (approx. 7.0 kb), (S-a) long sVEGFR-1 (approx. 6.3 kb), and (S-b) short sVEGFR-1 (approx.
2.4 kb). (C, D) Total RNA was isolated from several different types of human/murine cells (C) and murine organs (D), and equal amounts (10 lg) of RNAs were analyzed by
Northern blot using probe 1 or murine VEGFR-1 cDNA as a probe.
T. Saito et al. / FEBS Letters 587 (2013) 2179–2185 21813. Results
3.1. Identiﬁcation of full-length VEGFR-1 and several splice variants of
sVEGFR-1 mRNA in Northern blot analysis
Both full-length and soluble forms of VEGFR-1 transcripts are
synthesized as splice isoforms from the VEGFR-1 gene. However,
the expression proﬁles of each transcript have not been fully eluci-
dated. To investigate the expression of these transcripts, we per-
formed Northern blotting using 4 probes around intron 13 of the
VEGFR-1 gene. Probe 1 was located at the N-terminus site of the
VEGFR-1 cDNA and was used to detect both full-length VEGFR-1
and sVEGFR-1 mRNAs (Fig. 1A). Probe 1 detected 3 bands that were
approximately 7.0, 6.3 and 2.4 kb in length (Fig. 1A-a; (F), (S-a) and
(S-b)). Probe 2 was located near the 50-end of intron 13 and wasexpected to detect only sVEGFR-1. It detected 2 bands of 6.3 and
2.4 kb in length, indicating the presence of two isoforms of
sVEGFR-1 (Fig. 1A-b; (S-a) and (S-b)). Probe 3, located near the
30-end of intron 13, detected only one band (Fig. 1A-c; (S-a)), sug-
gesting that the longer form (6.3 kb) of sVEGFR-1 contains almost
all of the sequence of intron 13. When we used probe 4, which cor-
responds to exon 14, it detected one 7.0 kb band but not the longer
(6.3 kb) form of sVEGFR-1 (Fig. 1A-d; (F)).
Taken together, 3 major bands were identiﬁed from our North-
ern blot analyses, namely (F) full-length VEGFR-1 (approx. 7.0 kb),
(S-a) long sVEGFR-1 (approx. 6.3 kb), and (S-b) short sVEGFR-1 (ap-
prox. 2.4 kb) (Fig. 1B).
We could also detect another faint band between long and short
sVEGFR-1 (Fig. 1A, black arrowhead). We speculate this corre-
sponds to another sVEGFR-1 splice variant (approx. 3.0 kb)
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Fig. 2. VEGF-A induces sVEGFR-1 expression through VEGFR-2 signaling. (A) HAECs were incubated with PlGF (50 ng/ml) or VEGF-A (50 ng/ml). Northern blot analysis was
performed using probe 1. Quantitative analysis is shown below the ﬁgure. (B) Western blot analysis using whole HAECs. Equal amounts of total cellular proteins (10 lg) were
subjected to SDS–PAGE, and then VEGFR-1 and sVEGFR-1 were detected using monoclonal anti-hVEGFR-1 antibody. Quantitative analysis is shown below the ﬁgure. (C)
HAECs were transfected with siRNA duplexes that targeted full-length VEGFR-1 or VEGFR-2, or scrambled siRNA, for 24 h, followed by treatment with VEGF-A (50 ng/ml) for
3 h. Northern blot analysis was performed using probe 1. Quantitative analysis is shown below the ﬁgure.
2182 T. Saito et al. / FEBS Letters 587 (2013) 2179–2185revealed by Sela et al. which is preferentially expressed in smooth
muscle cells [25].
3.2. Variable expression of full-length VEGFR-1 and sVEGFR-1 in
different cell types and organs
We next investigated the expression proﬁles of full-length VEG-
FR-1 and sVEGFR-1 mRNA in several different cell types and or-
gans. The major form of VEGFR-1 expressed in smooth muscle
cells and placental tissue was sVEGFR-1, whereas full length VEG-
FR-1 was the predominant form expressed in macrophages and
lung tissue (Fig. 1C and D). In contrast, various types of endothelial
cells express both full-length and sVEGFR-1 abundantly (Fig. 1C).These indicate that the ratio of full-length/sVEGFR-1 dynamically
changes depending on the cell type or organ.
3.3. VEGF-A induces the expression of sVEGFR-1
The ratio of sVEGFR-1/VEGF-A or sVEGFR-1/PlGF signiﬁcantly
correlates with the clinical course of patients with cancer [18]. In
this study, we hypothesized that there may be a link between
VEGF-A or PlGF and their endogenous inhibitor, sVEGFR-1, and
therefore investigated the interactions between VEGF-A signaling
and sVEGFR-1 expression using HAECs.
We found that sVEGFR-1 mRNA expression was upregulated by
VEGF-A, whereas PlGF had no effect. Since the abundance of
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Fig. 3. VEGF-A-induced expression of sVEGFR-1 was mediated via PKC-MEK signaling. (A) HAECs were pretreated with protein kinase C (PKC) inhibitor (calphostin C (1 lM)),
MEK inhibitor (u0126 (10 lM)), P13K inhibitor (LY294002 (10 lM)), or p38 MAPK inhibitor (SB203580 (10 lM)) for 30 min, followed by treatment with VEGF-A (50 ng/ml)
for 3 h. Northern blot analysis was performed using probe 1. Quantitative analysis is shown below the ﬁgure. (B) HAECs were pretreated with either PKC inhibitor
(calphostinC (1 lM)) or MEK inhibitor (u0126 (10 lM)) for 30 min, followed by treatment with TPA (100 pg/ml) for 3 h. Northern blot analysis was performed using probe 1.
Quantitative analysis is shown below the ﬁgure.
T. Saito et al. / FEBS Letters 587 (2013) 2179–2185 2183full-length VEGFR-1 was unchanged, this suggested that VEGF-A
affects the splicing process of the VEGFR-1 gene (Fig. 2A). Consis-
tent with this ﬁnding, Western blot analysis also showed that
VEGF-A induced an increase in the protein levels of sVEGFR-1 in
HAECs as well (Fig. 2B).3.4. VEGF-A induces sVEGFR-1 expression through VEGFR-2 signaling
We next examined the signaling pathways that regulate
VEGF-A-mediated sVEGFR-1 induction. Knockdown of full-length
VEGFR-1 with siRNA signiﬁcantly enhanced the VEGF-A-induced
SV40 poly(A) signal
-45
LUC
VEGFR-1 promoter
-1160 +305 
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
ity
A 
n.s. 
n.s. 
VEGFR-1 intron13
+4840 -45
LUC
VEGFR-1 promoter
-1160 +305 
control  
TPA
  
V
E
G
F-A
B 
R
el
at
iv
e 
lu
ci
fe
ra
se
 a
ct
iv
ity
control  
T
PA
  
V
E
G
F- A
*
*
Fig. 4. PKC signaling upregulated the polyadenylation efﬁciency of intron 13.
Different manipulation of the poly(A) additional signal in two luciferase reporter
constructs. (A) A reporter construct driven by the VEGFR-1 promoter with the
poly(A) additional signal of SV40 intact. (B) A reporter construct also driven by the
VEGFR-1 promoter but with the poly(A) additional signal replaced by intron 13 of
the VEGFR-1 gene. The two constructs were transfected into HAECs, followed by
treatment with VEGF-A (50 ng/ml) or TPA (100 pg/ml) for 20 h. Luciferase reporter
assay was then performed.
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abrogated the induction of sVEGFR-1, indicating that VEGF-A
upregulates sVEGFR-1 through VEGFR-2-mediated pathways
(Fig. 2C).
3.5. VEGF-A-induced expression of sVEGFR-1 was mediated via PKC-
MEK signaling
VEGFR-2 is known to activate the protein kinase C (PKC)-MEK-
ERK pathway, the PI3K-Akt pathway, and the p38MAPK pathway
[26]. To further elucidate the signaling pathways underlying
VEGF-A-mediated sVEGFR-1 induction, we used inhibitors for each
of these pathways. HAECs were pretreated with protein kinase
inhibitors and then exposed to VEGF-A. VEGF-A-elicited induction
of sVEGFR-1 was signiﬁcantly attenuated by PKC (calphostin C) or
MEK (U0126) inhibitors, whereas PI3K (LY294002) or p38MAPK
(SB203580) inhibitors did not have any effect (Fig. 3A). Further-
more, 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (100 pg/ml),
an activator of PKC, signiﬁcantly induced the expression ofsVEGFR-1 mRNA without affecting that of full-length VEGFR-1,
and this induction was totally abrogated by PKC (calphostin C) or
MEK (U0126) inhibitors (Fig. 3B). Pretreatment with higher con-
centrations (20–100 ng/ml) of TPA partially restored sVEGF-R1
induction in the presence of PKC inhibitor (data not shown). Collec-
tively, these results indicate that VEGF-A induces sVEGFR-1
expression through the VEGFR-2-PKC-MEK pathway.
3.6. VEGF-A responsive elements exist in intron 13 of the VEGFR-1 gene
It is well known that intron 13 is critically important for the
alternative splicing of VEGFR-1 gene. Therefore, we examined the
contribution of intron 13 during the process of VEGF-A-elicited
sVEGFR-1 induction using luciferase reporter assay. We generated
a luciferase reporter construct that was driven by the VEGFR-1 pro-
moter (Fig. 4A), and a second reporter construct that was also dri-
ven by the VEGFR-1 promoter but with the SV40 poly(A) additional
signal of this plasmid replaced by intron 13 of the VEGFR-1 gene
(Fig. 4B). Neither VEGF-A nor TPA affected VEGFR-1 promoter
activity (Fig. 4A), whereas both VEGF-A and TPA signiﬁcantly in-
creased the luciferase activity of the reporter plasmid containing
intron 13 of VEGFR-1 (Fig. 4B). These results suggest that VEGF-A
or TPA responsive elements exist in intron 13 of the VEGFR-1 gene,
which is critically important in its alternative splicing process.
4. Discussion
While both full-length and soluble forms of VEGFR-1 are syn-
thesized as splice variants from VEGFR-1 gene [8], how this alter-
native splicing is regulated has remained largely unknown. In this
study, we showed that VEGF-A regulates alternative splicing of the
VEGFR-1 gene and induces the expression of sVEGFR-1 mRNA
without affecting full-length VEGFR-1 expression. We also demon-
strated that the induction was mediated via VEGFR-2 signaling
pathways. This result correlates well with the observation that
PlGF, a speciﬁc ligand for VEGFR-1, had no effect on sVEGFR-1
expression. Interestingly, speciﬁc knockdown of full-length VEG-
FR-1 signiﬁcantly enhanced the induction of sVEGFR-1 by VEGF-
A, a result that may be explained by an enhanced bioavailability
of the VEGFR-2 pathway owing to the reduction in levels of VEG-
FR-1 that would otherwise act as a ‘‘decoy’’ receptor [5].
By using inhibitors for the various pathways that are involved in
signaling through VEGFR-2, we further revealed that the induction
of the expression of sVEGFR-1 by VEGF-A is mediated through the
PKC-MEK pathway. Since it is well known that the major angio-
genic signals of VEGF-A is largely transduced through VEGFR-2
and its downstream PKC-MEK-ERK pathways [27], these ﬁndings
lend further support to the concept that VEGF-A-induced
sVEGFR-1 expression can indeed operate as a negative feedback
system to regulate angiogenic processes.
Lastly, we investigated the molecular mechanisms by which
VEGF-A upregulates sVEGFR-1 expression. The critical region ele-
ment for sVEGFR-1 production exists in intron 13 of the VEGFR-1
gene, where premature polyadenylation serves as a signal for alter-
native splicing [8,28,29]. While we demonstrated that there is a
VEGF-A responsive element within intron 13 of the VEGFR-1 gene
with the use of luciferase reporter assays, the precise molecular
mechanisms of how VEGF-A regulates the alternative splicing at
this intron of the VEGFR-1 gene still remains to be elucidated.
Angiogenesis is an important process in reproduction [30],
embryonic development [31], and wound repair [32], but excessive
angiogenesis can also result in numerous diseases such as athero-
sclerosis, arthritis, diabetic retinopathy and cancer progression
[32,33]. It follows that tight spatial and temporal regulation of
angiogenesis is vital and necessary, yet surprisingly little is known
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genic processes except for vasohibin [34]. Vasohibin has recently
been identiﬁed as an endothelium-speciﬁc inhibitor of angiogene-
sis that is upregulated by VEGF-A and FGF-2. Therefore, the speciﬁc
induction of sVEGFR-1 by VEGF-A revealed by this study may oper-
ate in another additional negative feedback system in VEGF-A-in-
duced angiogenic processes.
In this study, we demonstrated that the expression proﬁles of
the full-length and soluble VEGFR-1 genes signiﬁcantly differ be-
tween tissues and cell types. The molecular mechanisms underly-
ing such cell type-speciﬁc differences need to be elucidated in
order to fully understand the precise mechanisms of angiogenesis.
Moreover, the functional difference between the long form and
short form sVEGFR-1 also has to be further investigated. One pos-
sibility, for example, is that the long 30UTR of the long form of
sVEGFR-1 may perhaps affect the post-transcriptional regulation
of sVEGFR-1 by modulating its mRNA stability or translational
efﬁciency.
In conclusion, we found that VEGF-A induces sVEGFR-1 in vas-
cular endothelial cells through regulating the alternative splicing
of the VEGFR-1 gene. Our ﬁndings further indicate that there is a
clear interaction between VEGF-A and its negative regulator,
sVEGFR-1, and therefore the modulation of this system can be a
novel target for future therapeutic applications.
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